Health Wire Cabo Verde: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Cabo Verde.

Press releases published on May 18, 2026

May 18, 2026

Pennant Group to Participate in the 2026 RBC Global Healthcare Conference

Indeterminate GlobeNewswire

May 18, 2026

New Lusardi Tower Opens to Patients This Week At Scripps Memorial Hospital Encinitas

Indeterminate GlobeNewswire

May 18, 2026

ATI Advisory Launches Public Dashboard on C-SNPs and Eligible Populations

Indeterminate GlobeNewswire

May 18, 2026

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

Indeterminate GlobeNewswire

May 18, 2026

Precision Optics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Indeterminate GlobeNewswire

May 18, 2026

Certara to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

May 18, 2026

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

May 18, 2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

May 18, 2026

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

Indeterminate GlobeNewswire

May 18, 2026

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland

Indeterminate GlobeNewswire

May 18, 2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Indeterminate GlobeNewswire

May 18, 2026

DeGen Medical Expands Patient-Specific Spine Platform

Indeterminate GlobeNewswire

May 18, 2026

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD  

Indeterminate GlobeNewswire

May 18, 2026

Communiqué de presse : ATS : Les données de phase 2 démontrent la supériorité de l'efdoralprin alfa par rapport au traitement de substitution standard pour atteindre des taux de fAAT plus élevés dans le DAAT

Indeterminate GlobeNewswire

May 18, 2026

Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment

Indeterminate GlobeNewswire

May 18, 2026

Joyce University of Nursing and Health Sciences Earns Maximum 10-Year CCNE Accreditation for MSN Program

Indeterminate GlobeNewswire

May 18, 2026

Cystic Fibrosis Advocate Shares the Invisible Burden of Living with CF on YourUpdateTV

Indeterminate GlobeNewswire

May 18, 2026

Capitol Hill Briefing To Spotlight Critical Health Care Services for Adults With Communication Disorders

Indeterminate GlobeNewswire

May 18, 2026

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Indeterminate GlobeNewswire

May 18, 2026

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

Indeterminate GlobeNewswire